Clin2
NCT06115070Possibly a fitNot yet recruiting

Clot-busting medicine for mild stroke without limb weakness

ThrombosisAcute Ischemic Stroke (AIS)

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests whether giving a clot-busting drug (alteplase) within 4.5 hours helps people who have a mild stroke with symptoms like vision problems, facial drooping, or trouble speaking, but no weakness in an arm or leg.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
390 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You had a stroke that is mild (NIHSS score of 5 or less) with no arm or leg weakness, but you have other symptoms like vision changes, face drooping, or trouble speaking.
  • You started having symptoms within the last 4.5 hours (or woke up with symptoms within 4.5 hours of the midpoint of your sleep).
  • You are 18 years or older.
  • You do not plan to have a procedure to remove a clot (endovascular treatment).
  • You have not had a major bleed in the brain, recent head injury, or certain conditions that increase bleeding risk.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06320431Recruiting· Phase 3
Clot-busting drug for disabling stroke within 4.5 hours

This trial tests a clot-busting drug called tenecteplase for people having a disabling ischemic stroke (a clot blocking blood flow to the brain). It aims to see if the drug can help improve recovery when given within 4.5 hours of symptoms starting.

Sydney, Barangaroo
NCT06749834Recruiting· Phase 3
Clot-busting drug after stroke in people on newer blood thinners

This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.

Hangzhou, Zhejiang
NCT06841978Not yet recruiting· Phase 3
Clot-dissolving treatment for recent stroke patients

This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.

NCT06556446Recruiting
Clot-busting drug after stroke if on blood thinner

This study looks at whether giving a clot-busting medicine (IV thrombolysis) is safe and effective for people who have had a stroke and also recently took a direct oral anticoagulant (DOAC). If you've taken a DOAC in the last 48 hours, this trial may help doctors decide the best treatment for you.

Innsbruck
NCT06571149Recruiting· Phase 4
Blood thinners and clot-busting drugs for stroke

This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.

Eisenstadt
NCT06241677Recruiting
Clot-busting therapy for stroke patients on blood thinners

This study tests whether giving a clot-busting medicine through an IV can help people who have had a stroke while taking a common blood thinner (apixaban, dabigatran, edoxaban, or rivaroxaban). It may be an option if your last dose of the blood thinner was 12 to 48 hours before the stroke and you arrive at the hospital within 4.5 hours of symptoms starting.

Hong Kong

Hear when a new Thrombosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.